Last reviewed · How we verify
HyQvia
HyQvia is a Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin Biologic drug developed by Takeda. It is currently FDA-approved for Primary Immunodeficiency (PI). Also known as: Immune Globulin Subcutaneous (Human), 10% Solution with rHuPH20, IGI 10% with rHuPH20, 10%) with recombinant human hyaluronidase (rHuPH20).
HyQvia (Takeda) is a subcutaneous immunoglobulin replacement therapy for primary immunodeficiency, currently marketed with 22 clinical trials and 14 publications supporting its use. The drug represents an advance in immunoglobulin delivery, utilizing recombinant human hyaluronidase to enable subcutaneous administration with extended dosing intervals compared to traditional SCIG therapies. With established clinical efficacy in PI management and a marketed status, HyQvia addresses a significant unmet need in immunodeficiency treatment by improving patient convenience and quality of life. The therapy has demonstrated commercial viability in the immunoglobulin replacement market, competing within the broader immunotherapy landscape for chronic immunodeficiency management.
At a glance
| Generic name | HyQvia |
|---|---|
| Also known as | Immune Globulin Subcutaneous (Human), 10% Solution with rHuPH20, IGI 10% with rHuPH20, 10%) with recombinant human hyaluronidase (rHuPH20), Immune Globulin Infusion 10% (Human) (IGI |
| Sponsor | Takeda |
| Drug class | Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin |
| Target | Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Primary Immunodeficiency (PI)
Common side effects
- Local reactions
- Headache
- Antibody formation against rHuPH20
- Fatigue
- Nausea
- Pyrexia
- Vomiting
- Erythema
- Pruritus
- Increased lipase
- Abdominal pain
- Back pain
Drug interactions
- Anticoagulants
- Live vaccines
- Drugs metabolized by CYP450 enzymes
Key clinical trials
- Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
- A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (PHASE2, PHASE3)
- A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (PHASE3)
- A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
- A Study of TAK-881 and HyQvia in Healthy Adults (PHASE1)
- At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
- Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP (PHASE3)
- A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HyQvia CI brief — competitive landscape report
- HyQvia updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about HyQvia
What is HyQvia?
What is HyQvia used for?
Who makes HyQvia?
Is HyQvia also known as anything else?
What drug class is HyQvia in?
What development phase is HyQvia in?
What are the side effects of HyQvia?
What does HyQvia target?
Related
- Drug class: All Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin drugs
- Target: All drugs targeting Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Primary Immunodeficiency (PI)
- Also known as: Immune Globulin Subcutaneous (Human), 10% Solution with rHuPH20, IGI 10% with rHuPH20, 10%) with recombinant human hyaluronidase (rHuPH20), Immune Globulin Infusion 10% (Human) (IGI
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing